ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Buy at Wall Street Zen

Posted by Geri Gentry on Aug 11th, 2026

Wall Street Zen lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a strong-buy rating to a buy rating in a report issued on Saturday.

Several other equities analysts have also issued reports on the company. Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They issued a “hold” rating and a $91.00 price objective for the company. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Finally, Guggenheim reiterated a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $105.83.

Read Our Latest Report on ANI Pharmaceuticals

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $75.76 on Friday. The company has a market cap of $1.72 billion, a PE ratio of 16.33 and a beta of 0.44. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a 1 year low of $70.15 and a 1 year high of $99.50. The company’s 50-day moving average is $81.00 and its two-hundred day moving average is $79.26.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

Insider Activity

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the sale, the director owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas Haughey sold 2,000 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,825 shares of company stock valued at $2,110,571 in the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares in the last quarter. Penn Capital Management Company LLC increased its holdings in shares of ANI Pharmaceuticals by 2,058.9% during the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after purchasing an additional 131,030 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $2,487,000. Artemis Investment Management LLP acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $1,706,000. Finally, CenterBook Partners LP acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $1,518,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.